Skip to content

Isotonic Saline for Children With Bronchiolitis

Isotonic Saline for Children With Bronchiolitis - a Randomized Controlled Non-inferiority Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05902702
Enrollment
300
Registered
2023-06-15
Start date
2023-09-30
Completion date
2029-09-30
Last updated
2023-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis, Respiratory Disease, Asthma in Children, Viral Infection, Acute Respiratory Infection

Keywords

Nebulized saline, Nasal saline drops, Nasal saline irrigation, Respiratory severity score

Brief summary

The goal of this randomized clinical trial is to investigate the optimal supportive treatment of bronchiolitis in infants from 0-12 months of age. The main question\[s\] it aims to answer are: * To investigate whether isotonic saline should be used as supportive treatment for children with bronchiolitis, and if so, identify the optimal route of administration. The primary outcome is duration of hospitalization. * To investigate the current epidemiology of the viral pathogens causing bronchitis in children in Denmark, and to assess whether children infected with specific pathogens might benefit from treatment with isotonic saline. The children are randomized after inclusion through computer randomization to one of the 3 arms in the study: 1. Nebulized isotonic saline 2. Nasal irrigation with isotonic saline 3. No treatment with saline The investigators will compare treatment with saline (both methods) with no treatment, and the investigators will also compare the two methods of delivery of saline (nebulized vs. nasal irrigation).

Detailed description

Design: An investigator-initiated, multicenter, open label, three-arm randomized, controlled non-inferiority trial. Study sites: Seven pediatric departments in eastern Denmark (Slagelse Hospital, Holbæk Hospital, Zealand University Hospital Roskilde, Copenhagen University Hospital Hvidovre, Copenhagen University Hospital Herlev, Nordsjaellands Hospital, and Nykoebing Falster Hospital). Participants: Children aged 0-12 months admitted to a pediatric department or emergency department in eastern Denmark with bronchiolitis, whose parents provide informed consent for participation. Randomization: Participating children are randomized 1:1:1 through computer randomization to either nebulized isotonic saline, nasal irrigation with isotonic saline or no isotonic saline therapy at all. Participating children will have a nasal sample collected and tested for a panel of viral pathogens. Excess material (1 ml nasal lining fluid) from upper airway respiratory samples will be stored in a research biobank until 31.12.2030 and used for sub-phenotyping of bronchiolitis and for developing personalized treatment and prediction of later asthma by means of host transcriptomics and metabolomics, 16S sequencing of the airway microbiome and meta-transcriptomics. All other treatment is given according to standard of care guidelines. Sample size: By including 249 children in total (83 in each arm) the investigators can prove non-inferiority of nasal irrigation or nebulized saline relative to no saline with a non-inferiority limit of 12 hours admission, alpha 2.5% and a power of 80%. The investigators aim to include 300 children in total to account for dropouts. Recruitment: Children will only be included if both parents provide informed consent. Perspectives: This study may improve current practice for supportive treatment of children with bronchiolitis. If saline is found to be helpful, it may be implemented into global guidelines. If no effect of saline is found, physicians may stop spending resources and manpower on an ineffective and potentially unpleasant treatment. Second, if saline is effective, but nasal irrigation proves to be non-inferior to nebulization, it may also reduce the workload of nurses, and possibly duration of hospitalization, because the treatment can be delivered by the parents at home. Moreover, the parents are empowered to manage their child's illness themselves, potentially improving the experience of parents as well as the affected child.

Interventions

The intervention will constitute nebulized isotonic saline.

The intervention will constitute isotonic saline administered as nasal drops.

Sponsors

Copenhagen University Hospital at Herlev
CollaboratorOTHER
Zealand University Hospital
CollaboratorOTHER
Copenhagen University Hospital, Hvidovre
CollaboratorOTHER
Holbaek Sygehus
CollaboratorOTHER
Nordsjaellands Hospital
CollaboratorOTHER
Nykøbing Falster Hospital
CollaboratorUNKNOWN
Slagelse Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome assessor will receive anonymized data for analysis.

Intervention model description

An investigator-initiated, multicenter, open label, three-arm randomized, controlled non-inferiority trial.

Eligibility

Sex/Gender
ALL
Age
1 Days to 12 Months
Healthy volunteers
No

Inclusion criteria

* Children aged 0-12 months, whose parents give informed consent to participate, with symptoms of bronchiolitis including at least one of: * Runny nose * Dry and persistent cough * Labored breathing (tachypnea, retractions, nasal flaring) * Grunting * Cyanosis or apnea * Wheezing or crackles on auscultation * O2 saturations below 92 % * Difficulties feeding

Exclusion criteria

* Children with cystic fibrosis or other serious congenital lung diseases * Children in whom treatment with short-acting beta-2 agonist is initiated (as this is delivered in nebulized isotonic saline).

Design outcomes

Primary

MeasureTime frameDescription
Duration of hospitalization0-7 days typically (max 14 days)In hours

Secondary

MeasureTime frameDescription
Number of participants being readmitted after discharge30 days after dischargeIf readmitted to the hospital
Respiratory severity scoreDuring admission (up to day 14)Respiratory Severity Score with Heart Rate (RSS-HR), scale from 0-12, higher score means worse outcome.
Number of participants needing oxygen therapyDuring admission (up to day 14)Need for oxygen therapy
Number of participants needing transfer to ICU or SICUDuring admission (up to day 14)Transfer to the intensive care unit or semi-intensive care unit
Health-related Quality of LifeUp to one month after dischargeHealth-related Quality of Life questionnaire developed by Díez-Gandía et al. (PMID: 34488668) including 12 items. Item responses will be scored using the following algorithm (unweighted method): (1) Each response item will be assigned a value according to its gravity (1 = best level or 9 = worst level). (2) The sum of the scores will be standardized using the min-max normalization to a 0-1-point scale, with 1 indicating the best quality of life and 0 the worst.
Number of participants needing respiratory supportDuring admission (up to day 14)The need for respiratory support with nasal continuous positive airway pressure or high-flow oxygen therapy.
pCO2During admission (up to day 14)Highest pCO2 measured
Number of participants needing to switch treatmentDuring admission (up to day 14)Clinician-initiated switch to the opposite treatment from the one they were randomized to
Number of participants with visible distressDuring admission (up to day 14)Visible distress in the child during delivery of treatment
Parents satisfactionUp to one month after dischargeParents satisfaction with the given treatment, questionnaire developed by the investigators exploring satisfaction of 3 items on a scale from 1-10 (total score from 3-30) where higher score means better outcome.
Fluid supplementsDuring admission (up to day 14)Requirement of fluid supplements either by nasogastric tube or intravenous

Contacts

Primary ContactAnn-Marie M Schoos, MD, PhD
annms@regionsjaelland.dk+45 20681250
Backup ContactMaren J Rytter, MD, PhD
mjry@regionsjaelland.dk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026